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INTRODUCTION
Major depressive disorder (MDD) is a common psychiatric illness with high morbidity that
poses a huge burden to healthcare systems worldwide. According to the World Health
Organization, the lifetime prevalence of MDD is approximately 3–17% globally (Richards, 2011).
However, after major, but limited, success with selective serotonin reuptake inhibitors (SSRIs)
or serotonin–noradrenaline reuptake inhibitors, few promising therapeutic approaches have been
developed from preclinical studies using current animal models of MDD, despite intensive research
involving laborious methods and substantial costs.
Traditionally, most research using rodent models of MDD has been conducted using relatively
young adult animals, aged approximately 8 weeks, to avoid any involvement of aging-related
biological factors. The major rationale of this strategy is based on epidemiological findings that the
occurrence of MDD displays a robust peak in young adults rather than in the elderly (Jorm, 2000;
Copeland et al., 2004; Blazer and Hybels, 2005). Further, the elderly may have aging-related factors
rendering this group an inappropriate model of “genuine” MDD. A critical question is whether
this strategy is indeed appropriate. Despite the consistent findings of a lower lifetime prevalence
rate of MDD in the elderly than in young adults, there remain persistent doubts regarding the
underdiagnosis of MDD in the elderly (Hoertel et al., 2013). It has been heavily argued that patients
diagnosed with MDD in youth will often be rediagnosed with a bipolar disorder (Lish et al., 1994;
Leonpacher et al., 2015). Thus, a considerable number of cases of MDD in young adults may be
misdiagnosed. In addition, MDD in the elderly has distinct biological/environmental backgrounds
and consequences compared with that in young adults.
In this opinion article, we primarily shed light on the significance of MDD in the elderly (known
as geriatric MDD or late-onset depression) and problems associated with the methodology of
preclinical studies undertaken to investigate the characteristics and treatment of this disorder.
INFLUENCES OF AGING ON PHYSIOLOGICAL FUNCTIONS
First, it is widely accepted that functional changes in motor or cognitive functions in the
elderly, including those related to learning and memory, are attributed to aging-induced
physiological changes (Mora et al., 2007; Grady, 2012; Limdenberger, 2014). For example, aging of
Abbreviations: Aβ, amyloid-β; AD, Alzheimer’s disease; BDNF, brain-derived neurotropic factor; CSF, cerebrospinal fluid;
MDD, major depressive disorder; SSRI, selective serotonin reuptake inhibitor.
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the dopaminergic system is one of the major factors responsible
for motor disturbances in the elderly. However, the patients
with Parkinson’s disease may demonstrate dysregulated habits
and learning abilities before manifesting motor disturbance as
a result of dorsal striatum damage (Hadj-Bouziane et al., 2013).
This type of inconspicuous dysfunction may be sufficient to
affect the ability of the elderly to perform normal daily activities,
which consequentially generates frustration, exhaustion, and
compromised self-esteem. Meanwhile, the effect of aging on
the serotonergic or noradrenergic system, which plays a pivotal
role in the pathophysiology of MDD (Blier and El Mansari,
2013; Fakhoury, 2015), remains to be elucidated in rodents and
humans, although a decline in serotonin transport in the elderly
both in human and non-human primates (Kakiuchi et al., 2001;
Yamamoto et al., 2002) may result not only in mood instability
but also in being short-tempered or easily giving up in the
elderly (Miyazaki et al., 2012). Besides neurotransmitters, aging-
induced decreases in neurotropic factors, such as brain-derived
neurotropic factor (BDNF), which is essential for neuronal
plasticity, may also be involved in cognitive dysfunction (Burke
and Barnes, 2006; Tapia-Arancibia et al., 2008).
Current major hypotheses to explain the molecular
mechanisms underlying MDD, such as a deficit of BDNF
(Duman and Monteggia, 2006), dopamine (Nestler and
Carlezon, 2006; Dreher et al., 2008), serotonin, or stress-induced
attenuation of neurogenesis (Lazarov et al., 2010; Hamilton et al.,
2013). However, these potential mechanisms are more suitable
for aged than younger brains because these alterations commonly
become eminent during the natural course of aging. Other aging-
related macro/microstructural changes, such as vascular changes,
weakened immune/cytokine responses, compromised redox
status, a loss of dendritic spines, and reduced neuronal plasticity,
may also account for the pathophysiology of MDD (Burke and
Barnes, 2006; Lucin and Wyss-Coray, 2009; Currais and Maher,
2013; Gutchess, 2014). All these physiological systems maintain
resilience as long as they function appropriately. However,
once malfunction begins, it may result in the loss of resilience,
namely an increased prevalence of damaging symptoms such as
cognitive impairment (Butters et al., 2004), pseudo-dementia,
and delusions (Alexopoulos, 2005), which occur less often in
young adults. These symptoms are related to the higher rate of
recurrence of MDD in the elderly (Maeshima et al., 2012) and
complicate the treatment of these patients. Executive functions
and decision-making abilities may be similarly affected (Buckner,
2004; Breton et al., 2015; Samanez-Larkin and Knutson, 2015).
CAUSAL RELATIONSHIP BETWEEN MDD
AND DEMENTIA IN THE ELDERLY
Second, researchers has recently argued the possibility ofMDD as
a precursor or risk factor for Parkinson’s disease (Fang et al., 2010;
Inoue et al., 2010; Shen et al., 2013; Gustafsson et al., 2015), mild
cognitive impairment (Panza et al., 2010; Richard et al., 2013;
Snowden et al., 2015), dementia with Lewy bodies (Boot et al.,
2013), vascular dementia (Barnes et al., 2012; Diniz et al., 2013;
Taylor et al., 2013), Alzheimer’s disease (AD; Green et al., 2003;
Ownby et al., 2006; Geerlings et al., 2008; Barnes et al., 2012; Diniz
et al., 2013), or general aging–related cognitive disorders (Byers
and Yaffe, 2011; da Silva et al., 2013; Sibille, 2013). As mentioned
before, MDD in the elderly often accompanies pseudo-dementia,
which alleviates when MDD is attenuated but not completely
in many cases (Alexopoulos, 2005), implying a continuum of
deterioration fromMDD to dementia in the elderly. In support of
this concept, MDD in the elderly often involves a greater degree
of severe brain atrophy and/or white matter hyperintensity than
that in the age-matched healthy controls (Herrmann et al., 2008;
Dotson et al., 2009; Köhler et al., 2010; Tham et al., 2011;
Geerlings et al., 2013; Ribeiz et al., 2013; Khundakar and Thomas,
2014).
Given that depression in the elderly is a precursor of
dementia, depression should always precede the onset of
dementia, and concomitantly coexist at the initial or transitional
stage of dementia. However, given the considerable prevalence
of depression without cognitive impairment in the elderly
(Pellegrino et al., 2013), in some cases, MDD may boost, rather
than prelude, dementia. At this point, whether a history of
depression is a precursor for dementia remains an issue of debate.
Even in case that MDD is not the precursor for
neurodegenerative disorders, the process of neurodegeneration,
in turn, may cause vulnerability against MDD from a very early
stage. For example, Lewy bodies or senile plaques appear in the
brain at a relatively early point in life, while the consequence
could be subclinical in terms of cognitive function. However, the
appearance of plaques, albeit a subthreshold of the manifestation
of motor or cognition impairment, may provide sufficient
vulnerability to stress for triggering MDD by gradually damaging
physiological resilience (Jagust, 2013). In this scenario, MDD is
not a precursor but rather a sinister overture of dementia. The
increase of Aβ levels in the cerebrospinal fluid (CSF) in patients
with MDD supports this idea (Osorio et al., 2014). Intriguingly,
SSRIs, which are not effective against the core symptoms of
AD, were found to decrease Aβ levels in CSF in both healthy
individuals and AD model mice (Sheline et al., 2014), suggesting
that AD pathology is reversible, at least to some extent, and is
not sufficient to develop dementia by itself.
FURTHER PROMISING RELATIONSHIPS
BETWEEN STRESS AND DEMENTIA
Meanwhile, the causal relationship between chronic stress and
dementia has been repeatedly supported by many preclinical
studies (Csernansky et al., 2006; Sotiropoulos et al., 2008; Dong
and Csernansky, 2009; Rissman, 2009). For example, chronic
stress or glucocorticoid augmentation induces tau pathology
in rat brain (Catania et al., 2009; Carroll et al., 2011), as
well as cognitive impairment in rats (Rissman et al., 2007,
2012; Sotiropoulos et al., 2011). Corticotropin releasing factor
accelerates Aβ production in AD models (Dong et al., 2012).
In addition, chronic mild stress accelerates the onset and
progression of AD-like phenotypes in Tg2576 mice (Cuadrado-
Tejedor et al., 2012). Moreover, stress not only induces
posttraumatic stress disorder-like phenotypes but also more
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easily elevates Aβ levels in AD model animals compared with
wild-type animals (Justice et al., 2015). However, in these studies,
MDD-like symptoms or treatment-resistance to antidepressants
were not assessed. Thus, at this point, it is still inconclusive
whether they are the models of dementia which includes
depression as one of the initial symptoms or pseudo-dementia in
elderly MDD. Meanwhile, clinical studies have not yet addressed
the effect of psychological stress on dementia. On the contrary,
it is well known that cognitive enrichment or social engagement
can delay the onset of dementia, even with the same load of
AD pathology (Stern, 2006; Fratiglioni and Wang, 2007), which
further supports the idea that MDD may boost dementia as an
additional factor by affecting these positive factors.
OTHER FACTORS THAT EXAGGERATE
MDD IN THE ELDERLY
Other factors that are not directly connected to the aging
of the brain, such as the presence of comorbid illnesses and
corresponding pharmacological treatment for these illnesses,
social isolation, or spousal loss, could predispose, or deteriorate
MDD in the elderly. Overall, in the elderly, vulnerability to stress
is more profound. Thus, it is highly likely that depression-like
phenotypes may be more easily inducible by various stressors in
the elderly than in young adults (summarized in Figure 1A). In
addition, because of the abovementioned multiple complicated
factors, MDD in the elderly demonstrates diverse individual
differences both in symptoms and responses to antidepressants,
resulting in treatment failure and higher recurrence in the elderly
than in young adults (Reynolds et al., 1999).
ESSENTIAL PRECLINICAL STUDIES FOR
ELUCIDATING THE MOLECULAR
PATHOPHYSIOLOGY UNDERLYING MDD
IN THE ELDERLY
Taken together, two current models regarding the relationship
between MDD, and dementia in the elderly are summarized
(Figure 1B). In the first model, stress induces dementia-related
pathology and MDD independently and the co-existence of the
two will result in dementia, indicating that the presence of MDD
promotes the development of dementia (i.e., booster model). In
this sense, the full remission of MDD in the elderly may be
more important to prevent future dementia. In the secondmodel,
stress induces dementia-related pathology to a point sufficient
for the development of dementia; MDD appears as a prodromal
symptom of dementia (i.e., precursor model). In this case, to halt
the ensuing symptoms, it is important to elucidate the molecular
FIGURE 1 | (A) Relationship between aging-related factors in patients with dementia and MDD. (B) Two models for understanding the causal relationship between
MDD and dementia.
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mechanisms underlying the development and manifestation of
depression (Gareri et al., 2002; Krishnan, 2002; Alexopoulos and
Kelley, 2009; Naismith et al., 2012).
We propose a methodology to verify which model is correct.
To verify the “booster” model, it is important to determine
whether AD-related pathology is sufficient to induce MDD-like
symptoms without other stress in rodents (Llorens-Martin et al.,
2011). In turn, it would be intriguing to address the effect of
subclinical AD-related pathology on the vulnerability to stress
in animal models of dementia before the exhibition of robust
cognitive or motor dysfunction at certain ages by exposure to
other types of stress that may induce MDD. Relatively young
or middle-aged animals are appropriate for this purpose and
are used in the most current preclinical studies. On the other
hand, to verify the second model, resistance to treatment with
antidepressants and persistence of these pathological alterations,
cognitive impairments, which are the hallmarks of dementia,
and MDD-like symptoms need to be fully addressed in stress-
induced AD models. Given that MDD is a part of dementia as
this scenario, it is expected that there will be very fewer resilience
cases in the elderly than in young adults. In addition, other
types of “pure” psychological stressors that evoke MDD-like
phenotypes, such as social defeat (Berton et al., 2006), should
be examined to reproduce similar consequences. Hence, such
studies require aged rodents.
Our proposed studies may appear to be an amalgamation
of various interdependent aging-related factors rather than
a “genuine” model of MDD. However, they may mimic
both actual clinical situations and the brain states of
patients at the onset of MDD better than conventional
animal models of MDD. These approaches may allow us to
conclude a causal relationship between MDD and dementia
in the elderly. In addition, they may help to develop novel
treatment regimens to not only alleviate the symptoms
of MDD but also prevent the onset of dementia in the
elderly.
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